8-K: iRhythm Q3 Revenue Soars 30.7%, Boosts 2025 Outlook

iRhythm Technologies reported robust third-quarter 2025 financial results with revenue up 30.7% year-over-year and increased its full-year 2025 guidance, alongside an updated executive severance policy.

Summary

• Q3 2025 revenue reached $192.9 million, a 30.7% increase from $147.5 million in Q3 2024.
• Gross margin improved to 71.1%, a 230-basis point increase compared to Q3 2024.
• Net loss significantly narrowed to $5.2 million, or $0.16 diluted loss per share, from $46.2 million ($1.48 diluted loss per share) in Q3 2024.
• Adjusted net loss was $2.0 million, or $0.06 diluted loss per share, compared to $39.2 million ($1.26 diluted loss per share) in Q3 2024.
• Unrestricted cash, cash equivalents, and marketable securities stood at $565.2 million as of September 30, 2025.
• Increased fiscal year 2025 revenue guidance to between $735 million and $740 million.
• Increased fiscal year 2025 adjusted EBITDA margin guidance to approximately 8.25% to 8.75% of revenues.
• The Board approved an Amended and Restated Executive Change in Control and Severance Policy on October 29, 2025, enhancing benefits for qualifying terminations to align with market practices and retain key executives.

Sentiment

Score: 9

Explanation: The company reported strong Q3 financial results with significant revenue growth, improved gross margin, and a substantially reduced net loss. The increased full-year guidance for both revenue and adjusted EBITDA margin, coupled with the expectation of achieving annual free cash flow positivity for the first time, indicates robust operational performance and a very positive outlook. The advancements in its innovation pipeline and reinforcing clinical evidence further contribute to a highly favorable sentiment.

Positives

• Strong revenue growth of 30.7% year-over-year in Q3 2025, reaching $192.9 million.
• Significant improvement in gross margin to 71.1%, a 230-basis point increase.
• Substantial reduction in net loss from $46.2 million in Q3 2024 to $5.2 million in Q3 2025.
• Healthy unrestricted cash, cash equivalents, and marketable securities balance of $565.2 million.
• Increased full-year 2025 revenue guidance to $735 million to $740 million.
• Increased full-year 2025 adjusted EBITDA margin guidance to 8.25% to 8.75%.
• Achieved record free cash flow generation during the quarter and anticipates being free cash flow positive on an annual basis for the first time.
• Continued momentum in core long-term continuous monitoring business and sustained demand for Zio AT.
• Progress within innovative value-based care accounts and contribution from international markets.
• Positive clinical evidence from AVALON, CAMELOT, and AMALFI studies reinforcing Zio's clinical value.
• Advancing innovation pipeline with FDA submission for next-generation Zio MCT solution and early work in sleep diagnostics.

Negatives

• Still reporting a net loss of $5.2 million for Q3 2025, despite significant improvement.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual outcomes and results to differ materially, as described in the "Risk Factors" section of other SEC filings, including the Form 10-Q expected to be filed on or about October 30, 2025.
• The company may determine in its sole discretion that it cannot provide COBRA premiums or replacement payments without violating applicable law (e.g., Section 2716 of the Public Health Service Act), in which case eligible employees would not receive further benefits.
• Payments under the Executive Change in Control and Severance Policy may be subject to reduction if they constitute "parachute payments" under Section 280G of the Internal Revenue Code and would be subject to excise tax, to ensure the executive receives the greater after-tax amount.
• The company reserves the right to amend the Executive Change in Control and Severance Policy without consent to comply with Section 409A of the Code or avoid additional tax imposition.

Future Outlook

iRhythm projects full-year 2025 revenue between $735 million to $740 million and an adjusted EBITDA margin ranging from approximately 8.25% to 8.75% of revenues. The company anticipates being free cash flow positive on an annual basis for the first time in its history. Innovation efforts include the submission of its next-generation Zio MCT solution to the FDA and early work in sleep diagnostics. Upcoming data presentations are scheduled for the American Heart Association Scientific Sessions from November 7-10, 2025.

Management Comments

• "iRhythm delivered another quarter of strong performance, reflecting the scalability of our platform and the growing adoption of our differentiated technology across the healthcare ecosystem." Quentin Blackford, President and Chief Executive Officer.
• "With third quarter of 2025 revenue up 30.7% year-over-year, we continue to demonstrate consistent execution and durable demand across core accounts as well as continued growth into emerging innovative channel partnerships." Quentin Blackford, President and Chief Executive Officer.
• "Our ongoing expansion into primary care and population health programs, combined with meaningful progress in EHR integration and new clinical evidence, reinforces our leadership in proactive cardiac monitoring." Quentin Blackford, President and Chief Executive Officer.
• "We are advancing our innovation pipeline including submission of our next-generation Zio MCT solution to the FDA and early work in sleep diagnostics while driving operational efficiency and profitable growth." Quentin Blackford, President and Chief Executive Officer.
• "Importantly, we achieved record free cash flow generation during the quarter and anticipate this year to be free cash flow positive on an annual basis for the first time in company history." Quentin Blackford, President and Chief Executive Officer.
• "iRhythm’s mission remains clear: to transform cardiac care through actionable insights, empowering clinicians and improving outcomes for millions of patients worldwide." Quentin Blackford, President and Chief Executive Officer.

Industry Context

iRhythm's strong performance reflects broader trends in digital health, particularly the growing adoption of wearable biosensors and cloud-based data analytics for proactive disease detection and prevention. The company's expansion into primary care and population health programs, coupled with EHR integration, aligns with the industry's shift towards more integrated and accessible healthcare solutions. Its focus on long-term continuous cardiac monitoring positions it well within the evolving landscape of cardiovascular diagnostics.

Comparison to Industry Standards

• The AVALON, CAMELOT, and AMALFI real-world evidence and randomized clinical trials reinforce the clinical superiority and increased atrial fibrillation detection of iRhythm's Zio long-term continuous monitoring service. These studies provide internal validation of Zio's value proposition against other ambulatory cardiac monitoring strategies (CAMELOT compared to other strategies in Medicare beneficiaries) and remote screening methods (AMALFI for asymptomatic AF).
• The filing does not provide specific comparisons to direct competitors' financial results or product performance benchmarks.

Corporate Governance

Legal Proceedings

• The company incurred intellectual property litigation costs, excluding third-party attorneys' fees and expenses, related to patent litigation brought against it by Welch Allyn, Inc. and Bardy Diagnostics, Inc., subsidiaries of Baxter International, Inc.

Stakeholder Impact

• Shareholders: Likely positive impact due to strong financial performance, increased guidance, and anticipated free cash flow positivity, which could lead to increased share value.
• Executives: Directly benefits from enhanced severance and change-in-control protections, providing greater financial security and retention incentives.
• Patients/Clinicians: Continued innovation (Zio MCT, sleep diagnostics) and reinforcing clinical evidence for Zio services suggest ongoing improvements in diagnostic tools and patient outcomes for cardiac care.
• Employees (non-executive): No direct impact mentioned, but overall company growth and operational efficiency could imply a stable or growing work environment.

Next Steps

• Present upcoming data at the American Heart Association (AHA) Scientific Sessions in New Orleans, Louisiana, from November 7-10, 2025.
• Continue advancing the innovation pipeline, including the submission of the next-generation Zio MCT solution to the FDA.
• Continue early work in sleep diagnostics.
• File the Form 10-Q on or about October 30, 2025.

Key Dates

Recommendation

The company delivered exceptional Q3 2025 results, significantly exceeding prior performance with a 30.7% revenue increase and a 230-basis point improvement in gross margin. The substantial reduction in net loss and the upward revision of full-year 2025 revenue and adjusted EBITDA margin guidance demonstrate strong operational execution and a positive trajectory towards profitability. The anticipation of achieving annual free cash flow positivity for the first time in company history is a major milestone. Coupled with ongoing innovation in cardiac monitoring and expansion into new diagnostic areas, these factors indicate robust growth potential and strong financial health, making it a compelling investment opportunity.

Keywords

iRhythm Technologies, IRTC, Q3 2025 Earnings, Cardiac Monitoring, Digital Health, Zio, Revenue Growth, EBITDA Margin, Executive Severance, Corporate Governance, Medical Devices, Healthcare Technology